Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury
about
Neuroprotection for traumatic brain injuryCytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction.The Role of Substance P in Secondary Pathophysiology after Traumatic Brain Injury.Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategiesTreatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's diseaseSerum substance P levels are associated with severity and mortality in patients with severe traumatic brain injury.Substance p regulates puberty onset and fertility in the female mouse.Inflammation in acute CNS injury: a focus on the role of substance PExperimental diffuse brain injury results in regional alteration of gross vascular morphology independent of neuropathology.Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.Blood-brain barrier and traumatic brain injury.Neuropeptide substance P and the immune response.N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis.Synergism between fibronectin and transforming growth factor-β1 in the production of substance P in monocytes of patients with myelofibrosis.Serum Levels of Substance P and Mortality in Patients with a Severe Acute Ischemic Stroke.The role of substance P in epilepsy and seizure disorders.Enhanced expressions of neurodegeneration-associated factors, UPS impairment, and excess Aβ accumulation in the hippocampus of mice with persistent cerebral toxocariasis.
P2860
Q26824808-73EC2E9B-D0C4-4D38-8E88-D47B15512685Q30390049-E64FF822-429F-4765-82D0-D2E2A35741ACQ33843032-008FF290-6C31-4BCA-9391-16D9377F6C23Q34147023-E04EA1C0-4C2E-481A-90AF-E4C0B0256EECQ34224832-4697052C-7F09-48CD-B345-87B8D279932FQ35584890-59AE8866-2592-4A48-A963-32127F2732F8Q35603388-4D69A940-4F7B-4EFB-86DE-6980B1FB0454Q36546990-527618CE-FAE6-4624-882D-1DCA407DD0D3Q36815751-2091B068-DAED-41AF-B89C-06FADFF88FCEQ36925594-7EB1A7DC-AD3C-4161-823D-D801049876D5Q38170329-C914BAF8-B1DA-4E9D-B95B-DAADE3A14CADQ38868323-491269CE-99A3-4551-BC87-643BF0723456Q38868878-400E671D-4F80-4BC2-A53D-29042DBE6A1BQ39294566-7F237780-E5D3-4A0E-8690-1814920734B5Q40684887-2C983EA7-0574-41FA-AE64-4D863A572E89Q44221614-AE6D32AD-2877-4D6A-80AA-0917290D5D64Q47134195-AD75B724-CBB9-4454-8D22-E79E839EE1AF
P2860
Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Substance P antagonists as a t ...... llowing traumatic brain injury
@en
Substance P antagonists as a t ...... lowing traumatic brain injury.
@nl
type
label
Substance P antagonists as a t ...... llowing traumatic brain injury
@en
Substance P antagonists as a t ...... lowing traumatic brain injury.
@nl
prefLabel
Substance P antagonists as a t ...... llowing traumatic brain injury
@en
Substance P antagonists as a t ...... lowing traumatic brain injury.
@nl
P2860
P1433
P1476
Substance P antagonists as a t ...... llowing traumatic brain injury
@en
P2093
Corinna van den Heuvel
Robert Vink
P2860
P2888
P356
10.1016/J.NURT.2009.10.018
P577
2010-01-01T00:00:00Z
P5875
P6179
1021431552